WO2004035622A2 - Il-15 antagonisten - Google Patents
Il-15 antagonisten Download PDFInfo
- Publication number
- WO2004035622A2 WO2004035622A2 PCT/CH2003/000666 CH0300666W WO2004035622A2 WO 2004035622 A2 WO2004035622 A2 WO 2004035622A2 CH 0300666 W CH0300666 W CH 0300666W WO 2004035622 A2 WO2004035622 A2 WO 2004035622A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- cell
- fusion protein
- nucleic acid
- animal
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 6
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 116
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 100
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 100
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 98
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 98
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 84
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 84
- 239000013598 vector Substances 0.000 claims abstract description 66
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 238000002054 transplantation Methods 0.000 claims abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 157
- 241001529936 Murinae Species 0.000 claims description 49
- 210000000056 organ Anatomy 0.000 claims description 38
- 241001465754 Metazoa Species 0.000 claims description 35
- 230000009261 transgenic effect Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 210000001557 animal structure Anatomy 0.000 claims description 29
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 28
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 17
- 238000001890 transfection Methods 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 12
- 210000001109 blastomere Anatomy 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 210000004504 adult stem cell Anatomy 0.000 claims description 8
- 230000001605 fetal effect Effects 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 5
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 210000000287 oocyte Anatomy 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 238000002689 xenotransplantation Methods 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 6
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 102000056003 human IL15 Human genes 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 241001122315 Polites Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101100273730 Homo sapiens CD5 gene Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000044446 human CD46 Human genes 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Definitions
- the invention relates to fusion proteins from a wild-type E -15 and an IgG-Fc fragment and to their production and use for inhibiting immune reactions and for the prophylaxis and / or therapy of secondary transplant and / or autoimmune diseases.
- T cells An effective immune response is initiated by the activation of T cells in the immune system, which is triggered by an antigen or mitogen.
- the activation of the T cells requires numerous cellular changes, these include e.g. the expression of cytokines and their receptors. These cytokines include IL-15 and E -2.
- IL-15 and IL-2 are known growth factors that play a significant role in the proliferation and differentiation of human and murine T cells, macrophages, natural killer (NK) cells, cytotoxic T cells (CTL), lymphocyte-activated Killer (LAK) cells and in the costimulation of B cells that have been activated, for example, by anti-immunoglobulin (anti-IgM) or phorbol esters.
- NK natural killer
- CTL cytotoxic T cells
- LAK lymphocyte-activated Killer
- anti-IgM anti-immunoglobulin
- phorbol esters anti-immunoglobulin
- the proliferation of these cells increases an organism's immune response.
- LL-15 was first described as a secretory cytokine that induces the proliferation of IL-2 dependent murine cytotoxic T cells (CTLL-2).
- CTLL-2 IL-2 dependent murine cytotoxic T cells
- IL-15 has been characterized as a 162 amino acid precursor protein with a leader sequence of 48 amino acids, ie a mature protein of 114 amino acids in length (Grabstein et al., (1994) Science 264 (5161): 965-8).
- IL-15 is produced in epithelial and fibroblast cell lines as well as peripheral blood monocytes. Its specific mRNA was also found in the placenta, skeletal muscles and kidneys (Grabstein et al., Supra)
- IL-15 and IL-2 also have homologous structures. Both molecules bind to at least three separated receptor subunits on the membrane of T cells, the beta and gamma subunit complexes via which the signal transduction is the same, while the alpha subunit is specific for the binding of IL-15 and IL-2, respectively . It was found that antibodies directed against the alpha subunit of the IL-2 receptor had no effect on the IL-15 binding to its specific alpha subunit (Grabstein et al., Supra), whereas antibodies directed against the beta Subunit of the IL-2 receptor were directed to block the activity of IL-15 (Giri et al, (1994) EMBO J., 13: 2822). Signal transduction takes place via the beta and gamma subunits of IL-15.
- autoimmune diseases in particular type I diabetes mellitus (Bottazzo, GF, et al, (1985) N Engl J Med 113: 353), rheumatoid arthritis, multiple sclerosis, chronic liver diseases, inflammatory bowel diseases, transplant-anti- Graft versus host disease (GVHD) and graft rejection (Sakai et al., (1998) Gastroenterology, 114 (6): 1237-1243; Kivakakk et al., (1998) Clin Exp Immunol, 111 (1): 193197).
- inimun-competent cells are transmitted from a genetically non-identical organism, these cells react to the recipient organism (GVHD) (Janeway CA and Travers P., Spectrum Verlag, German edition 1995 p. 467).
- Humoral effectors are antibodies of different specificity, such as, for example, antibody-dependent cell-mediated cytotoxicity and antibodies against structures of the donor HLA system.
- Cellular effectors are in particular cytotoxic T cells in connection with macrophages (Immunologie, Janeway CA and Travers P., Spectrum Verlag, German edition 1995, pp. 522-8).
- One therapeutic approach is to suppress the humoral or cellular immune response by immunosuppressia, in particular antagonistic IL-15 or IL-2 antibodies or IL-15 or IL-2 antagonists.
- IL-15 antagonists which change the binding behavior of IL-15 to its receptor. These antagonists were obtained by introducing mutation (s) into the wild-type IL-15 sequence. For example, a mutation at amino acid position 56 (aspartate) [position 8 after cleavage of the leader sequence] has been described, through which binding to the alpha subunit of the IL-15 receptor took place, however binding to the beta subunit was prevented (WO 96/26274). In another approach, the interaction with the gamma subunit was inhibited by a mutation at amino acid position 156 (glutamine) [position 108 after cleavage of the leader sequence] (WO 96/26274; WO 97/41232).
- IL-15 antagonists described are mutated IL-15 (mut-IL-15) sequences which have antagonistic effects either by themselves or as a fusion protein.
- fusion proteins are polypeptides consisting of an N-terminal mut-IL-15 fragment and a C-terminal Fc fragment, in particular a murine IgG2a or human IgGl (WO 97/41232; Kim et al., (1998) J Immunol ., 160: 5742-5748).
- Fc fragment crystallizable fragment
- the two other identical Fab fragment antigen binding fragments of an antibody have antigen binding activity (Immunology, Janeway CA and Travers P., German edition (1995), p. 117 and the following).
- IL-15 molecules have a changed primary, secondary and tertiary structure compared to the wild-type IL-15 and therefore have different degradation points, so that degradation products occur which do not occur naturally in the cells, and can have a toxic effect on the organism.
- the nature and extent of such and other side effects cannot be foreseen in detail.
- Immunosuppressants are dependent. Usually because that is inadequate Knowledge of the side effects of long-term use of such immunosuppressive agents is urgently needed to rule out or at least limit these side effects.
- a major disadvantage is that the generally systemic administration of such immunosuppressants leads to their distribution throughout the organism and does not ensure the local presence at the site of the transplanted cells, tissue or organ.
- inhibiting T cell proliferation throughout the organism can cause infections, toxic breakdown products or even cancer.
- the object of the present invention is therefore to produce an immunosuppressant which has no or hardly any side effects in an organism in which an immune response is to be inhibited.
- mutated IL-15 molecules or fusion proteins consisting of a mut-IL-15 and an Fc fragment, have an antagonistic effect on IL-15 by inhibiting or changing the receptor binding behavior.
- a fusion protein consisting of an N-terminal wild-type IL-15 and a C-terminal Fc fragment, in particular a murine IgG2a, also has an antagonistic effect, although an agonistic effect would be expected in itself . Only by attaching an Fc fragment to a naturally occurring, normally an immunostimulating IL-15 molecule, the mechanism of action could be reversed, i.e. the inhibition of an immune response.
- the invention therefore relates to a fusion protein composed of a wild-type IL-15 on the one hand and an IgG-Fc fragment on the other hand, with the exception of a murine IgG2b-Fc fragment.
- a fusion protein according to the present invention is to be understood as the expression product of a fused gene.
- a fused gene is created by linking two or more genes or gene fragments, which creates a new combination.
- a wild-type IL-15 according to the present invention is understood to mean the naturally occurring IL-15, as described, for example, in Grabstein et al, (1994) Science 264 (5161): 965-8 or allelic variants thereof.
- Fc (fragment crystallizable) fragment is to be understood as the fragment of an antibody which does not bind any antigens, for example an antibody molecule which lacks the variable domains, or also partially or completely the first constant domain of the heavy and light chains.
- the Fc fragment can come from a natural source, can be produced recombinantly and / or can be synthesized. Appropriate methods are known to the person skilled in the art.
- the Fc fragment of the fusion protein according to the invention is an immunoglobulinG (IgG), specifically a human or murine IgGl, a human IgG2, a murine IgG2a, a human or murine IgG3 or a human IgG4, preferably a human IgGl or a murine IgG2a, especially especially an IgGl.
- IgGs were preferably used from the hinge region.
- the flexible region in the Ig molecule is referred to as the hinge region.
- murine IgG2b (Schlomchik, MJ, (1987 ), Nature 328, 805-811), human IgG3 (Huck, S. et al., (1986), Nucleic Acids Res. 14 (4): 1779-1789), murine IgG3 (Wels et al., (1984) , EMBO J., 3 (9): 2041-2046) and human IgG4 (Pink et al., (1970), Biochem. J., 117 (1): 33-47).
- the fusion protein according to the invention is preferably a chimeric fusion protein, for example containing a wild-type IL-15 and a heterologous IgGl -Fc fragment or a heterologous IgG2a-Fc fragment.
- the fusion protein according to the invention comprises the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 SEQ ID NO: 4 or SEQ ID NO: 5.
- the invention further relates to a nucleic acid which codes for a fusion protein which on the one hand contains a wild-type IL-15 and on the other hand an IgG-Fc fragment, with the exception of a murine IgG2b-Fc fragment.
- the nucleic acid according to the invention preferably codes for a wild-type IL-15 and a human or murine IgGl, a human IgG2, a murine IgG2a, a human or murine IgG3 or a human IgG4, particularly preferably for a human IgGl or a murine IgG2a, most preferably for an IgGl.
- the nucleic acid according to the invention preferably encodes a fusion protein with one of the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5.
- the nucleic acid according to the invention contains the DNA sequences SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10.
- a nucleic acid in the sense of the present invention means an RNA or DNA, in particular genomic DNA, cDNA or synthetic DNA, which was synthesized, for example, at the phosphoramidation level. Combinations and or modifications of nucleotides of these nucleic acids are also included. This term also includes single and double-stranded nucleic acids.
- nucleic acids which contain functionally linked components, for example one or more fused genes or active parts thereof coding for one or more fusion proteins according to the invention, and regulatable elements and / or regulative nucleotide sequences which influence the expression of the gene (s) in terms of quantity and / or as a function of time ,
- Regulable elements are, for example, promoters for constitutive or cell-specific or tissue-specific expression.
- Regulatory nucleotide sequences include, for example, leader sequences, polyadenylation sequences, e.g. an SV40 polyadenylation signal, enhancer sequences, IRES sequences and introns.
- leader sequences of the present inventions are, for example, those listed below: Igk leader:
- CD5 leader
- short native IL-15 leader 5 , -ATGTCTTCATTTTGGGCTGTTTCAGTGCAGGGCTTCCTAA-3 ,
- the components are functionally linked if they are linked in such a way that the sequence (s) of the genes or genes contained are or will be transcribed under the influence of the transcription regulation.
- the invention further relates to a vector which contains at least one nucleic acid according to the invention.
- Vectors in the sense of the present invention can be plasmids, shuttle vectors, phagemids, cosmids, adenoviral vectors, retroviral vectors, expression vectors and vectors with gene therapy effects.
- Expression vectors in the sense of the present invention include at least one nucleic acid according to the invention, at least one translation initiation signal, a translation termination signal and / or a polyadenylation signal for expression in eukaryotes.
- pIRES from Clontech, Palo Alto, USA
- pCI-neo vector from Promega, Madison, USA
- pCMV-Script from Stratagene, La Jolla, USA
- pCDNA vector Invitrogen, Paisley, UK
- Gene-therapeutic vectors according to the invention are, for example, virus vectors, for example adenovirus vectors, retroviral vectors or vectors which are based on replicons of RNA viruses (Lindemann et al., 1997, Mol. Med. 3: 466-76; Springer et al. , 1998, Mol. Cell. 2: 549-58; Khromykh, 2000, Curr. Opin. Mol. Ther .; 2: 555-69).
- Vectors with gene therapy effects can also be obtained by complexing the nucleic acid fragments according to the invention with liposomes. In lipofection, small unilamellar vesicles are made from cationic lipids by ultrasound treatment of the liposome suspension.
- the DNA is ionically bound to the surface of the liposomes in such a ratio that a positive net charge remains and the plasmid DNA is 100% complexed by the liposomes.
- DOTMA 1,2-dioleyloxypropyl-3-trimethylammonium bromide
- DPOE diioloxylphosphatidylethanolamine
- lipid formulations examples include DOTAP N- [1 - (2,3-dioleoyloxy) propyl] -N, N, N-trimethyl-ammoniumethyl-sulfate or DOGS (TRANSFECTAM; diocta-decylamidoglycylspermin).
- Excipients that increase the transport of nucleic acids into the cells can be, for example, proteins or peptides that are bound to DNA or synthetic peptide-DNA molecules that enable the transport of the nucleic acid into the nucleus of the cell (Schwartz et al., 1999, Gene Therapy 6: 282; Branden et al.
- Auxiliaries also include molecules that enable the release of nucleic acids into the cytoplasm of the cell (Planck et al., 1994, J. Biol. Chem. 269, 12918; Kichler et al., 1997, Bioconj. Chem. 8, 213) or for example liposomes (Uhlmann and Peimann, 1990, Chem. Rev. 90, 544).
- the invention relates to a cell which contains at least one nucleic acid according to the invention and / or at least one vector according to the invention.
- This cell is preferably a precursor cell, an immortalized cell or a stem cell, in particular a pluripotent or multipotent embryonic, fetal, neonatal or adult stem cell.
- pluripotent embryonic stem cells or cell lines can be obtained from the inner cell mass of blastocytes (Robertson, Embryo-derived stem cell lines, in Teratocarcinomas and embryonic stem cells: a practical approach, Robertson, editor, IRL Press, Washington DC, 1987)
- Particularly preferred stem cells derived from adult tissue include, for example, neuronal stem cells, stem cells from the bone marrow, mesenchymal stem cells, hematopoietic stem cells, epithelial stem cells, stem cells from the digestive tract and duct stem cells.
- Cells according to the invention are, for example, epithelial cells, vascular cells, liver cells, heart cells, skin cells, muscle cells, nerve cells, bone marrow cells, CHO cells (ovary cells) and cells from the pancreas, from the kidney, from the eye or from the lungs.
- the cell according to the invention is in particular a mammalian cell, including a human cell.
- This cell can originate, for example, from a human, a mouse, a rat, a guinea pig, a rabbit, a cow, a goat, a sheep, a horse, a pig, a dog, a cat or a monkey, preferably from a human ,
- the cells of the invention can also be used to express a heterologous gene.
- the cell according to the invention is preferably in the form of a cell line.
- a cell line according to the invention can be produced by transfection, transformation or infection of a cell line with a nucleic acid according to the invention or a vector according to the invention with the aid of methods which Those skilled in the art are familiar, for example transfection, transformation, electroporation, microinjection or infection.
- the invention further relates to a medicament comprising at least one fusion protein according to the invention, at least one nucleic acid according to the invention, at least one vector according to the invention and / or at least one cell according to the invention and, if appropriate, suitable auxiliaries and / or additives.
- auxiliaries and / or additives which are used, for example, to stabilize or preserve the medicament or diagnostic agent, are generally known to the person skilled in the art.
- auxiliaries and / or additives are physiological saline solutions, Ringer's dextrose, dextrose, Ringer's lactate, demineralized water, stabilizers, antioxidants, complexing agents, antimicrobial compounds, proteinase inhibitors and / or inert gases.
- the medicament according to the invention can e.g. for prophylaxis, therapy or diagnosis of diseases.
- diseases include, for example: rheumatic diseases, for example rheumatic arthritis, Sjogren's syndrome, scleroderma, dermatomyositis, polymyositis., Reiter's
- Type I or type II diabetes are Type I or type II diabetes.
- Autoimmune diseases of the thyroid gland for example Graves' disease, Hashimoto's thyroiditis, • Autoimmune diseases of the central nervous system, for example multiple sclerosis,
- Skin diseases for example psoriasis, neurodermatitis, inflammatory bowel diseases, for example Crohn's disease, Immune disorders, such as AIDS
- Post-transplant diseases for example graft rejection reactions and • tumor diseases.
- the medicament according to the invention is administered by the methods familiar to the person skilled in the art, for example intravenously, intraperitoneally, intramuscularly, subcutaneously, intracranially, intraorbitally, intracapsularly, intraspinally, transmuscularly, topically or orally.
- Other methods of administration are, for example, systemic or local injection, perfusion or catheter-based administration.
- the medicament according to the invention can, for example, be administered orally, e.g. Tablets or capsules, over the mucous membrane, e.g. the nose or oral cavity, in the form of sprays implanted in the lungs or in the form of disposers under the skin.
- Trans-dermal therapeutic systems are e.g. known from EP 0 944 398-A1, EP 0 916 336-A1, EP 0 889 723-A1 or EP 0 852 493-A1.
- the drug can be introduced into the organism either using an ex vivo approach in which the cells are removed from the patient, genetically modified, for example by DNA transfection, and then reintroduced into the patient or using an in vivo approach, in which vectors according to the invention having gene therapy effects are introduced into the patient's body, as naked DNA or using viral or non-viral vectors according to the invention or cells according to the invention.
- the dosage of drugs depends on several factors, for example on the body weight, the general state of health, the extent of the body surface, the age of the patient and the interaction with other drugs. Dosage also depends on the type of administration. The dosage must therefore be determined by the specialist in each individual case for each patient.
- the drug can be administered once or several times a day and over several days, and this can also be determined by a person skilled in the art.
- Another object of the invention relates to a human or animal organ-specific tissue and / or a human or animal mammalian organ, containing at least one fusion protein, at least one nucleic acid coding for said fusion protein, containing at least one vector containing at least one nucleic acid and / or at least one cell at least one said nucleic acid and / or at least one said vector, the fusion protein containing a wild-type IL-15 and an Fc fragment.
- the fusion protein of the human or animal organ-specific tissue according to the invention and / or the human or animal mammalian organ according to the invention preferably contains on the one hand a wild-type IL-15 and on the other hand a human or murine IgGl, a human IgG2, a murine IgG2a, a murine IgG2b, a human or murine IgG3 or a human IgG4, preferably a human IgGl or a murine IgG2a, in particular an IgGl, particularly preferably no murine IgG2b.
- Human or animal organ-specific tissue of the present invention can include, for example, tissue from the pancreas, including, for example, the Langerhan islet cells, as well as heart, heart muscle, kidney, liver, lung, spleen, cartilage, ligament, retina, cornea -, bone marrow, skin, nerve and / or muscle tissue.
- Human or animal mammalian organs of the present invention can be, for example, the pancreas, the heart, the pancreas, the kidney, the liver, the lungs, the spleen, the eye and / or the skin.
- the invention further relates to a transgenic non-human mammal which contains at least one fusion protein, at least one nucleic acid which codes for the fusion protein mentioned, at least one vector which contains at least one nucleic acid and or at least one cell which has at least one contains said nucleic acid and / or at least one vector, the fusion protein containing a wild-type IL-15 and an Fc fragment.
- the fusion protein of the transgenic non-human mammal according to the invention preferably contains on the one hand a wild-type IL-15 and on the other hand a human or murine IgGl, a human IgG2, a murine IgG2a, a murine IgG2b, a human or murine IgG3 or a human IgG4, preferably a human IgGl or a murine IgG2a, in particular an IgGl, particularly preferably no murine IgG2b.
- Trahsgenic animals generally show a tissue-specific increased expression of nucleic acids and are therefore very suitable for the analysis of, for example, immune reactions.
- Transgenic mice are preferably used.
- a non-human mammal according to the invention is, for example, a mouse, a rat, a guinea pig, a rabbit, a cow, a goat, a sheep, a horse, a pig, a dog, a cat or a monkey.
- the invention also relates to the uses of a fusion protein, a nucleic acid coding for the said fusion protein ; a vector containing at least one named nucleic acid and or a cell containing either at least one named nucleic acid and / or a named vector containing at least one nucleic acid mentioned, wherein the fusion protein contains a wild-type IL-15 and an Fc fragment, or a human or animal organ-specific tissue according to the invention and / or a human or animal mammalian organ according to the invention: to inhibit an IL-15 mediated cellular event, for inhibiting the interaction of an IL-15 with its receptor and / or for the prophylaxis and / or therapy of secondary transplant diseases, in particular transplant rejection reactions and / or autoimmune diseases.
- Another object of the invention is the use of a fusion protein, a nucleic acid coding for said fusion protein, a vector containing at least one named nucleic acid and / or a cell containing at least one named nucleic acid and / or said vector, the fusion protein being a wild-type Contains IL-15 and an Fc fragment, for the lysis of cells which express an IL-15 receptor.
- the fusion protein of the uses according to the invention preferably contains, on the one hand, a wild-type IL-15 and, on the other hand, a human or murine IgGl, a human IgG2, a murine IgG2a, a murine IgG2b, a human or murine IgG3 or a human IgG4, preferably a human IgGl or murine IgG2a, in particular an IgGl, particularly preferably no murine IgG2b.
- the uses according to the invention are preferably carried out in or in a human or animal mammal.
- a human mammal in the sense of the present invention is a human
- an animal mammal in the sense of the present invention is, for example, a mouse, a rat, a guinea pig, a rabbit, a cow, a goat, a sheep, a horse, to understand a pig, a dog, a cat or a monkey.
- the present invention furthermore relates to the use of the human or animal organ-specific tissue according to the invention and / or the human or animal mammalian organ according to the invention for transplantation into a human or animal mammal. It is preferably an auto, allo or xenograft.
- the transplant is the transfer of living material, e.g. of cells, tissues or organs, from one part of the body to another (autogenous transplantation) or from one individual to another (allogeneic, syngeneic and xenogeneic transplantation) (Klein, J. S, (1991) Immunologie, 1st edition, VHC Verlagsgesellschaft, Weinheim, p. 483) according to methods generally known to the person skilled in the art. A distinction is made between transplantation into another organism
- Another aspect of the invention is a method for producing a fusion protein according to the invention, which contains the following steps: a. Introducing at least one nucleic acid according to the invention and / or at least one vector according to the invention into a cell, and b. Expression of the nucleic acid under suitable conditions.
- nucleic acids, vectors and genes for example differentiation marker genes or transfection marker genes, into cells are well known to the person skilled in the art and comprise the methods customary in the prior art, for example electroporation, injection, transfection and / or transformation. These methods are particularly preferred when the substance is naked nucleic acids, in particular DNA.
- Suitable conditions for the expression of the nucleic acid can be created, for example, by expression vectors, for example by the aforementioned expression vectors and regulatable elements, for example promoters or regulative nucleic acid sequences.
- expression vectors also contain promoters suitable for the respective cell or the gene to be transcribed in each case.
- regulatable elements which enable constitutive expression in eukaryotes are promoters which are recognized by RNA polymerase II.
- Such promoters for constitutive expression in all cell and tissue types are e.g. the CDl lc promoter, pGk (phosphoglycerate kinase) promoter, the CMV (cytomegalovirus) promoter, the TK (thymidine kinase) promoter, the EFl (elongation factor l-alpha) promoter, the SV40 (Simian Virus) promoter, the RSV (Rous Sarcoma Virus) promoter and the pUB (Ubiquitin) promoter.
- CDl lc promoter e.g. the CDl lc promoter
- pGk phosphoglycerate kinase
- CMV cytomegalovirus
- TK thymidine kinase
- EFl elongation factor l-alpha
- SV40
- regulatable elements which enable cell-specific or tissue-specific expression in eukaryotes are promoters or activator sequences from promoters or enhancers of those genes which code for proteins which are only expressed in certain cell types.
- promoters are for example the insulin promoter for beta cells of the pancreas, the Sox-2 promoter for nerve cells, the albumin promoter for liver cells, the myosin heavy chain promoter for muscle cells, the VE-cadherin promoter for endo- thel cells and the keratin promoter for epithelial cells.
- Expression can also be controlled via regulatory nucleotide sequences that influence expression in terms of quantity and / or time. These include, for example, enhancer sequences, leader sequences, polyadenylation sequences, IRES sequences and introns.
- Another object of the invention is an in vitro method for producing a human or animal organ-specific tissue according to the invention and / or a human or animal mammalian organ according to the invention, which contains the following steps: a. Introducing into at least one stem cell, a precursor cell and / or an immortalized cell of a human or animal organ-specific tissue and / or a human or animal mammalian organ on the one hand encoding at least one nucleic acid for a fusion protein and / or at least one vector containing at least one named nucleic acid, wherein the fusion protein contains a wild-type IL-15 and an Fc fragment, and on the other hand at least one suitable differentiation marker gene, b. Differentiation of the cell from step a., C. Selection of the differentiated cell from step b. and d. Introduce the selected cell from step c. in at least one human or animal organ-specific tissue and / or in at least one human or animal mammalian organ.
- step a after, before or simultaneously with step a. at least one suitable transfection marker gene is introduced and after step a. preferably the transfected cell from step a. selected.
- suitable conditions for the differentiation of the cells can be created, for example, by adding growth factors which initiate the desired cell differentiation.
- the method according to the invention preferably contains a positive selection scheme.
- a marker gene for example a gene which transmits antibiotic resistance, is introduced into the cell before, during or after the differentiation step and is expressed under suitable conditions.
- suitable conditions can consist, for example, in that the expression of the marker gene is under the control of a promoter which is only active in the desired cells.
- the expression of the marker gene confers resistance to the antibiotic to the successfully differentiated cells.
- the selection of the cells following the differentiation can therefore easily be carried out, for example, by bringing the cells into contact with the corresponding antibiotic. Cells that do not contain the appropriate antibiotic resistance die, so that only the differentiated cells survive.
- contacting can take place, for example, by adding the active substances into the nutrient medium of a cell culture.
- An antibiotic according to the invention means an antibiotic against which the antibiotic resistance gene (s) used as the selection cassette according to the invention produces resistance. After the antibiotic has been added to the cultured stem cells, only those stem cells which contain the reporter gene expression vector essentially survive and differentiate.
- a second marker gene is preferably introduced into the cells, as a result of which a selection of the cells in which the introduction of the nucleic acid and / or the vector according to step a. the procedure was successful, can be carried out. This double selection makes it possible to obtain an approximately 90%, preferably approximately 95-100% pure cell population of the desired cells.
- Differentiation marker genes and transfection marker genes can be used for such selections, for example. As such, genes are predominantly used which impart resistance to certain toxic substances, for example antibiotics.
- antibiotics for example antibiotics.
- the most common antibiotics used in this context are neomycin, hygromycin (hph), zeocin (Sh ble) and puromycin (pacA).
- genes suitable for selection are, for example, genes which express the expression of surface molecules or of fluorescent markers, e.g. Regulate GFP, with the help of which the cells to be selected can be cleaned by cell sorting.
- Another object of the invention is a method for producing a transgenic non-human mammal according to the invention, which contains the following steps: a. Introduction into at least one oocyte, a stem cell, a precursor cell and / or an immortalized cell of a non-human mammal, on the one hand at least one nucleic acid coding for a fusion protein and / or at least one vector containing at least one said nucleic acid, wherein the fusion protein contains a wild-type IL-15 and an Fc fragment, and on the other hand at least one suitable transfection marker gene, b. Selection of the transfected cell from step a., C. Introduce the after step b. selected cell into at least one non-human mammalian blastocyte, d. Introduce the blastocyte from step c. into a non-human, preferably pregnant woman, mammal foster mother and e. Identification of the transgenic non-human mammal developed from said blastocyte.
- blastocytes are known to the person skilled in the art. It can be done, for example, by injection (Hogan, B., Beddington, R., Constantini, F. and Lacy, E., A laboratory Manual (1994), Cold Spring " Harbor Laboratory Press).
- a transgenic non-human mammal can be identified, for example, by extracting genomic DNA from the transgenic non-human mammal, e.g. from the tail of a mouse. In a subsequent PCR (polymerase chain reaction), primers are used which specifically recognize the transgene for the nucleic acid according to the invention. Integration of the transgene can be demonstrated in this way.
- genomic DNA is transferred to a membrane and detected by means of DNA probes, for example radioactively labeled DNA probes, which are specific for the transgene sought.
- Mammals by regenerating a non-human stem cell, oocyte, vrufler cell or immortalized cell to a transgenic non-human animal, in particular from transgenic mice, are known to those skilled in the art from DE 196 25 049 and U.S.
- a transgenic non-human mammal according to the invention can also be produced by direct injection of a nucleic acid according to the invention into the pronucleus (pronucleus) of a non-human mammal.
- transgenic animals in particular transgenic mice
- processes for the production of transgenic animals are also known to the person skilled in the art, inter alia. known from WO 98/36052, WO 01/32855, DE 196 25 049, US 4,736,866, US 5,625,122, US 5,698,765, US 5,583,278 and US 5,750,825 and include transgenic animals which are used, for example, via direct injection of vectors according to the invention into embryos or spermatocytes or can be generated via the transfection of vectors or nucleic acids in embryonic stem cells (Polites and Pinkert, in Pinkert, (1994) Transgenic animal technology, A Laboratory Handbook, Academic Press, London, UK, pages 15 to 68; Doetschman, in Pinkert, 1994 , supra, pages 115 to 146).
- Another object of the invention relates to a transgenic non-human mammal produced according to the method according to the invention described above and to its progeny.
- the stem cell is involved, which in the in-vitro method according to the invention mentioned for producing a human or animal organ-specific tissue according to the invention and / or a human or animal mammalian organ according to the invention and in the method for producing a transgenic non-inventive human mammal is used to generate a pluripotent or multipotent embryonic, fetal, neonatal or adult stem cell.
- An object of the invention is the use of a transgenic non-human according to the invention for the production of a cell, an organ-specific tissue and / or a mammalian organ for allo- and / or xenotransplantation.
- this can take place, for example, by means of an implantation method or by means of a catheter injection method through the blood vessel wall.
- extraction means the removal of the cell, tissue and / or organ mentioned from the organism of a transgenic non-human mammal according to the invention. Appropriate methods of removal are generally known to the person skilled in the art.
- the invention also relates to the use of a transgenic non-human mammal according to the invention, a human or animal organ-specific tissue according to the invention and / or a human or animal mammalian organ according to the invention for finding pharmacologically active substances and / or for identifying toxic substances.
- one such method could be to sow cells of the present invention on a 96-well microtiter plate, then to test one Add appropriate pharmacologically active or toxic substance and then analyze by cell count whether the substance has caused an increased death of the cells.
- pharmacologically active substance and toxic substance in the sense of the invention are understood to mean all those molecules, compounds and / or compositions and substance mixtures which, under suitable conditions, have a pharmacological or toxic influence on individual cells, individual tissues, individual organs or the whole Exercise organism of an animal or human mammal.
- Possible pharmacologically active substances and toxic substances can be simple chemical (organic or inorganic) molecules or compounds, nucleic acids or analogs of nucleic acids, anti-sense sequences of nucleic acids, peptides, proteins or complexes and antibodies. Examples are organic molecules that come from substance libraries and that are examined for their pharmacological or toxic activity.
- Pharmacologically active substances are, for example, active substances which exert an influence on: • the ability of cells to divide and / or survive, the secretion of proteins, eg insulin from beta cells of the pancreas, dopamine from nerve cells, muscle cell contraction and / or the migration behavior of cells. When applied to the entire organism of an animal or human mammal, this is to be understood as influencing, for example, the cardiovascular system, the nervous system and the metabolic activities.
- Toxic substances are, for example, active substances that
- the identified pharmacologically active substances and toxic substances can optionally be combined or used together with suitable additives and / or auxiliary substances for the production of a diagnostic agent or a medicament for the diagnosis, prophylaxis and or therapy of secondary transplant diseases and / or autoimmune diseases, as exemplified above.
- FIG. 1 a is an illustration of the amino acid sequence WT-IL-15-hIgG1
- FIG. 1 b is an illustration of the amino acid sequence WT-IL-15-mIgG2a
- Figure 2a is an illustration of the amino acid sequence WT-IL-15.
- Figure 2b is an illustration of the hlgGl amino acid sequence
- 2c is an illustration of the amino acid sequence mIgG2a
- Figure 3a is a picture of the amino acid sequence Igk8
- Figure 3b is a picture of the amino acid sequence 149-Fc
- 6a is an illustration of the nucleic acid sequence WT-IL-15
- FIG. 6b is an illustration of the nucleic acid sequence hlgGl
- FIG. 7 is an illustration of the nucleic acid sequence mIgG2a
- 8a is an illustration of the nucleic acid sequence of murine IgK leaders
- FIG. 8b is an illustration of the nucleic acid sequence of human CD5 leaders
- FIG. 8c is an illustration of the nucleic acid sequence of human CD4 leaders
- FIG. 8d is an illustration of the nucleic acid sequence of human IL5 leaders 2-leader
- Figure 9a is an illustration of the nucleic acid sequence of human MCP leaders
- Figure 9b is an illustration of the nucleic acid sequence of the short native human
- Figure 9c is an illustration of the nucleic acid sequence of the long native human
- FIG. 10 is an illustration of the nucleic acid sequence Igk8
- FIG. 11 is an illustration of the nucleic acid sequence 149-Fc
- FIG. 12 is an illustration of the inhibitory or proliferation-promoting effect of different protein constructs on the IL-15 mediated Proliferation of CTLL-2 cells.
- hlgGl stands for human IgGl
- mIgG2a stands for murine IgG2a.
- SEQ ID NO: 5 or an allelic variant thereof.
- nucleic acid coding for a fusion protein according to at least one
- nucleic acid according to (viii) containing the DNA sequence SEQ ID NO: 8 or an allelic variant thereof.
- nucleic acid according to (viii) containing the DNA sequence SEQ ID NO: 9. or an allelic variant of it.
- nucleic acid according to (viii) containing the DNA sequence SEQ ID NO: 10 or an allelic variant thereof.
- Medicaments containing at least one fusion protein according to one (i) to (vii) and (xiv), at least one nucleic acid according to one (viii) to (xiii), at least one vector according to (xv) and / or at least one cell according to one (xvi) to (xviii) and suitable auxiliaries and / or additives.
- transgenic non-human mammal containing at least one fusion protein, in particular for one (i) - (vii) and (xiv), at least one nucleic acid coding for said fusion protein, in particular for one (viii) - (xiii), at least one vector, in particular according to (xv), containing at least one nucleic acid and or at least one cell, in particular after (xvi) - (xviii), containing at least one nucleic acid and / or at least one vector, the fusion protein contains a wild-type IL-15 and an Fc fragment.
- a fusion protein in particular for a (i) - (vii) and (xiv), a nucleic acid, in particular for a (viii) - (xiii), a vector, in particular for a (xv), and / or one Cell, in particular according to a (xvi) - (xviii), the fusion protein containing a wild-type IL-15 and an Fc fragment or a human or animal organ-specific tissue and / or a human or animal mammalian organ according to (xxi) for the production of a Medicines to inhibit an IL-15 mediated cellular event.
- a fusion protein in particular for a (i) - (vii) and (xiv), a nucleic acid, in particular for a (viii) - (xiii), a vector, in particular for (xv), and / or a cell , in particular according to a (xvi) - (xviii), the fusion protein containing a wild-type IL-15 and an Fc fragment or a human or animal organ-specific tissue and / or a human or animal mammalian organ according to (xxi), for the manufacture of a medicament to inhibit the interaction of an IL-15 with its receptor.
- a fusion protein in particular after (i) - (vii) and (xiv), a nucleic acid, in particular after (viii) - (xiii), a vector, in particular after (xv), and / or one Cell, in particular according to an (xvi) - (xviii), wherein the fusion protein contains a wild-type IL-15 and an Fc fragment, for the manufacture of a medicament for the lysis of cells which express an IL-15 receptor.
- a fusion protein in particular for a (i) - (vii) and (xiv), a nucleic acid, in particular for a (viii) - (xiii), a vector, in particular for (xv), and / or a cell , in particular according to a (xvi) - (xviii), the fusion protein containing a wild-type IL-15 and an Fc fragment or a human or animal organ-specific tissue and / or a human or animal mammalian organ according to (xxi), for the manufacture of a medicament to
- Prophylaxis and / or therapy of secondary transplant diseases and / or autoimmune diseases are prophylaxis and / or therapy of secondary transplant diseases and / or autoimmune diseases.
- (xxii) comprising the following steps: a. Introduction into at least one oocyte, a stem cell, a precursor cell and / or an immortalized cell of a non-human mammal, on the one hand at least one nucleic acid, in particular after one (vii) - (xiii), coding for a fusion protein and / or at least one vector, in particular according to (xv), containing at least one named nucleic acid, the fusion protein containing a wild-type IL-15 and an Fc fragment, and on the other hand at least a suitable transfection marker gene, b. Selection of the transferred cell from step a., C. Introduce the after step b. selected cell into at least one non-human mammalian blastocyte, d. Introduce the blastocyte from step c. into a non-human mammal foster mother and e. Identification of the transgenic non-human mammal developed from said blastocyte.
- reagents such as cell culture media, enzymes, etc. were obtained from Invitrogen (formerly Gibco BRL / Life Technologies), Paisley, UK, and laboratory chemicals from Roth (Karlsruhe, DE).
- the starting point was a plasmid which in the vector pSecTagA (Invitrogen, Paisley, UK) the cDNA of a fusion protein from a mutated human IL-15 and a murine IgG2a-Fc part (Hinge-C2-C3, Kim et al. 1998, supra ) included.
- the fusion of IL-15 with the Fc part took place via a BamHI site, whereby an additional amino acid (aspartate) was inserted at the transition.
- the leader sequences of human IL-2, MCP-1, CD4 and CD5 can alternatively be cloned in.
- the vector pSecTagA was cut without insert with BglII (approach: 9 ⁇ g DNA, 4 ⁇ l 10X buffer 2, 26 ⁇ l water, 4 ⁇ l BglII (40 units) in a total of 40 ⁇ l, incubation for 2 h at 37 ° C.).
- the DNA was purified from enzyme and buffer on a Pharmacia S400 microspin column (Amersham-Pharmacia, Freiburg). 40 ⁇ l of the batch were mixed with 5 ⁇ l 10 ⁇ PCR buffer (Taq-Core-Kit, Qiagen, Hilden), 2 ⁇ l dNTPs (10 mM each, Taq-Core-Kit, Qiagen), 2 ⁇ l water and 1 ⁇ l (4 units ) DNA polymerase I (Klenow fragment) were added and incubated for 1 h at 37 ° C. in order to fill up the BglII site.
- the plasmid was then applied to a 1% agarose gel and the band eluted from the gel using the Concert Rapid-Gel-Extraction System. The entire batch was taken up in 100 ⁇ l of water. 7.5 ⁇ l thereof were ligated together with 7.5 ⁇ l water, 4 ⁇ l 5 ⁇ T4 ligase buffer and 1 ⁇ l T4 ligase (1U) for 1 h at room temperature. Half of the ligation approach was transformed into E.coli XL1 Blue (Stratagene, La Jolla, USA) according to the manufacturer's instructions.
- Ig-kappa leader + 10 additional amino acid mutIL-15-mIgG2a was cloned into the resulting plasmid again via the interfaces Nhel and Xbal.
- the original Ig-kappa leader + 10 amino acids + 5'-IL-15 part was then removed via an Nhel / BglII cut and replaced by an oligonucleotide cloning with the above-mentioned signal sequences.
- the fragment was as follows: 5'-NheI-Leader-IL-15-3 'with a BglII interface in the 5' section of the IL-15. Since this fragment was too long to be covered by a single oligonucleotide, two overlapping oligos and their complementary strands (4 oligonucleotides in total) were obtained from MWG-Biotech (Ebersberg) (sequence of the oligonucleotides see below). The single-stranded oligonucleotides were chosen so that overhanging ends were already available for cloning into the corresponding restriction sites (Nhel, Bglll). The oligonucleotides were first phosphorylated.
- each oligo were incubated in a 20 ⁇ l mixture with 2 ⁇ l 10 ⁇ forward buffer and 1 ⁇ l T4 polynucleotide kinase (10 U) for 1 h at 37 ° C. Subsequently, equimolar amounts of each strand and counter-strand oligo were annealed by heating to 95 ° C. and slowly cooling to room temperature. The double-stranded oligonucleotides were ligated overnight before cloning into the vector.
- the clones obtained were examined for their restriction pattern in the Miniprep (QIAamp DNA Mini Kit, Qiagen, Hilden). For this purpose, a triple digestion with Nhel / Bglll (restriction enzymes which directly cut out the leader used) and Xbal (cuts 3 'of the Fc part) was carried out.
- the DNA positive clones were isolated using the Qiagen Endofree Maxi kit according to the manufacturer's instructions and sequenced at GATC (Constance).
- the resulting plasmid (mutIL-15 101/108) -mIgG2a with purified Ig kappa leader was called Igk8.
- PCR was carried out using a forward primer with a BglII cleavage site at the 5 'end (IL-15fw3.1: 5'-attgaagatcttattcaatctatgc-3') and corresponding 3 'reverse primer (WT: 5'- ggatccgaagtgttgatgaacatttggacaatatgtacaaactctgcaaaaattc-3 '), (149: 5' - gggatcc- gaagtgttgatgaacatttgga-3 ') produced the individual mutants.
- HEK293 cells ATCC, Manassas, USA
- the proteins of the single mutants were prepared: To this was added per 150cm 2 plate 60 .mu.l lipofectamine2000 in 2 ml Optimem 1 medium and 30 ug plasmid DNA (IgK8, WT-Fc , 149-Fc) also diluted in 2 ml Optimem 1 medium. The two solutions were mixed and incubated for 30 minutes at room temperature. The DNA / liposome mixture was then added to approximately 80% confluent 150 cm 2 HEK-293 plates in the cell culture medium (Dulbecco's MEM + Glutamax + 10% FCS + 1% Pen / Strep).
- the medium was changed to ultraculture medium (Biowhittaker, Verviers, Belgium) and the cell culture medium was then left on the cells for 4 days.
- the cell culture supernatant was collected, passed through a folded filter (Schleicher and Schüll, Dassel) to remove the coarse cell components, then sterile filtered through a 2 ⁇ m bottle top filter (Nalgene-Nunc, Wiesbaden) and the IL-15-Fc - Fusion protein isolated by purification via Protein A Sepharose.
- Protein A-Sepharose (Amersham-Pharmacia, 50% ov / v in washing buffer) swollen in liter buffer (20 mM Tris / HCl, pH 8.5, 130 mM NaCl) were added per liter cell culture supernatant and the mixture was added Shaken 4 ° C overnight in an overhead shaker.
- the ProteinA-Sepharose was collected in an empty chromatography column and washed with at least 150 ml wash buffer. The protein was eluted from the column with 0.1 M glycine pH 2.5 in 1 ml fractions and immediately neutralized with 60 ⁇ l IM Tris / HCl, pH 9.5.
- the protein was dialyzed against PBS buffer and sterile filtered. The concentration of the protein was determined in the BCA assay (Pierce, Rockford, USA) and using silver gel and Western blot (first antibody: monoclonal mouse anti-human IL-15, BD Biosciences Pharmingen, San Diego USA, second antibody: POD-Goat anti mouse, Dianova, Hamburg), purity and identity checked. The functionality of the protein was then examined in the proliferation assay.
- CTLL-2 cells are murine cytotoxic T cells whose proliferation is dependent on IL-15 or IL-2 and which can therefore serve as indicators for the proliferation-inhibiting effect of antagonistic proteins.
- the cells were cultured in a medium consisting of RPMI1640 medium + 10% heat-activated fetal calf serum (FCS) + 1% Pen Strep + 20% advises T-Stim with ConA (Becton Dickinson Labware, Bedford, USA), a mixture different growth factors.
- FCS heat-activated fetal calf serum
- Pen Strep + 20% advises T-Stim with ConA (Becton Dickinson Labware, Bedford, USA), a mixture different growth factors.
- the cells were freed of the remaining growth factors necessary for the culture of the cells by washing twice with cell culture medium (RPMI 1640 + 10% FCS + 1% Pe ⁇ / Strep) and then also being taken up in this medium. For this, the cells were centrifuged at 349 g for 5 min, the supern
- the assay was carried out in flat bottom 96-well plates and 150 .mu.l of medium with 3 ⁇ 10 4 cell wells were used per well.
- the cells received only medium with 10% FCS, without additional factors.
- the positive control additionally contained recombinant human IL-15 (R&D Systems, Minneapolis, USA) in a concentration which allows a half-maximal proliferation of the cells (eg 12.5 pg / well). Negative and positive controls were pipetted in 6-fold batches.
- the cells were determined as for the positive control. wrote with recombinant IL-15 and received additionally purified protein of the double mutant 101/108 starting from Igk8, the wild-type protein (WT-Fc) or the single mutant (149-Fc). The highest concentration used was 2 ⁇ g per well and further 1: 2 dilutions (1 ⁇ g, 0.5 ⁇ g, 0.25 ⁇ g, 0.125 ⁇ g, etc.).
- mIgG2a (BD Biosciences Pharmingen, San Diego, USA) was used as non-specific antibody
- IL-2-Fc which contains a non-mutated cytokine component and thus the proliferation
- CTLA4-Fc also a structurally related fusion protein, which, however, should not influence the proliferation.
- Both of the latter proteins were obtained from Chimerigen (Allston, USA). All batches were pipetted in triplicate.
- the cells were incubated for 44 + 2 hours at 37 ° C. in the CO 2 incubator and then the proliferation was determined using the XTT-Cell Proliferation Kit (Röche) according to the manufacturer's instructions.
- the two components of the kit were mixed in a ratio of 1:50 (ie, 75 ⁇ l XTT labeling reagent + 1.5 ⁇ l electron coupling reagent).
- 75 ⁇ l of the mixture were added per well and the plate was measured after an incubation for 4 hours at 37 ° C. in a CO 2 incubator in an ELISA reader at 490 against 690 nm.
- WT-Fc, 149-Fc and protein of the double mutant 101/108 show an inhibitory effect on the IL-15 mediated proliferation of CTLL-2 cells.
- IL-2-Fc and IgG2a show a rather proliferation-promoting effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/530,987 US20060236411A1 (en) | 2002-10-14 | 2003-10-13 | Antagonists il-15 |
EP03750224A EP1554307A2 (de) | 2002-10-14 | 2003-10-13 | Il-15 antagonisten |
BR0315327-4A BR0315327A (pt) | 2002-10-14 | 2003-10-13 | Antagonistas de il-15 |
MXPA05003887A MXPA05003887A (es) | 2002-10-14 | 2003-10-13 | Antagonistas il - 15. |
JP2004543889A JP2006518583A (ja) | 2002-10-14 | 2003-10-13 | Il−15アンタゴニスト |
AU2003269659A AU2003269659A1 (en) | 2002-10-14 | 2003-10-13 | Antagonists il-15 |
CA002502316A CA2502316A1 (en) | 2002-10-14 | 2003-10-13 | Antagonists il-15 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02022869.8 | 2002-10-14 | ||
EP02022869 | 2002-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004035622A2 true WO2004035622A2 (de) | 2004-04-29 |
WO2004035622A3 WO2004035622A3 (de) | 2004-07-08 |
Family
ID=32103882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2003/000666 WO2004035622A2 (de) | 2002-10-14 | 2003-10-13 | Il-15 antagonisten |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060236411A1 (de) |
EP (1) | EP1554307A2 (de) |
JP (1) | JP2006518583A (de) |
KR (1) | KR20050049545A (de) |
CN (1) | CN1703423A (de) |
AU (1) | AU2003269659A1 (de) |
BR (1) | BR0315327A (de) |
CA (1) | CA2502316A1 (de) |
MX (1) | MXPA05003887A (de) |
PL (1) | PL376509A1 (de) |
RU (1) | RU2005114526A (de) |
WO (1) | WO2004035622A2 (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
CN100334112C (zh) * | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
WO2013004587A1 (en) | 2011-07-01 | 2013-01-10 | F. Hoffmann-La Roche Ag | Method for separation of monomeric polypeptides from aggregated polypeptides |
CN101360827B (zh) * | 2005-10-20 | 2013-03-20 | 国立医学与健康研究所 | IL-15Rα sushi结构域作为通过IL-15Rβ/γ的IL-15作用的选择性和有效的增强剂以及超激动剂(IL15Rα sushi-IL15)融合蛋白 |
WO2014207173A1 (en) * | 2013-06-27 | 2014-12-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases |
KR20170094341A (ko) * | 2014-12-19 | 2017-08-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 인터류킨 15 단백질 복합체 및 그의 용도 |
US11401312B2 (en) | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101831435B (zh) * | 2010-05-10 | 2013-09-11 | 昆山贝瑞康生物科技有限公司 | 小鼠il-15亚型蛋白的制备及其应用 |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
CN103501805B (zh) | 2011-01-18 | 2018-09-14 | 比奥尼斯有限责任公司 | 调节γ-C-细胞因子活性的组合物及方法 |
EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
CN108350032A (zh) | 2015-10-09 | 2018-07-31 | 比奥尼斯有限责任公司 | 调节γC-细胞因子活性 |
WO2018213828A1 (en) * | 2017-05-19 | 2018-11-22 | Case Western Reserve University | Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof |
AU2019271147A1 (en) | 2018-05-14 | 2020-12-17 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
KR20210021467A (ko) | 2018-05-14 | 2021-02-26 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법 |
EP3810171A4 (de) * | 2018-06-22 | 2022-04-06 | Cugene Inc. | Neuartige interleukin-15 (1l-15)-fusionsproteine und verwendungen davon |
EP4321530A3 (de) | 2018-09-27 | 2024-05-22 | Xilio Development, Inc. | Maskierte cytokinpolypeptide |
AU2020275877A1 (en) | 2019-05-14 | 2021-12-23 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
JP2022536898A (ja) | 2019-06-12 | 2022-08-22 | アスクジーン・ファーマ・インコーポレイテッド | 新規il-15プロドラッグおよびその使用方法 |
CN115087464A (zh) * | 2019-12-13 | 2022-09-20 | 科优基因公司 | 新型白介素-15(il-15)融合蛋白及其用途 |
US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041232A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5698765A (en) * | 1991-12-02 | 1997-12-16 | The Ontario Cancer Institute | Mouse having a disrupted CD4 gene |
WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
US5625122A (en) * | 1992-04-24 | 1997-04-29 | The Ontario Cancer Institute | Mouse having a disrupted lck gene |
JP3741447B2 (ja) * | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | エンドセリン−1遺伝子の機能が欠損したマウス |
JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
-
2003
- 2003-10-13 RU RU2005114526/13A patent/RU2005114526A/ru not_active Application Discontinuation
- 2003-10-13 JP JP2004543889A patent/JP2006518583A/ja active Pending
- 2003-10-13 KR KR1020057006381A patent/KR20050049545A/ko not_active Application Discontinuation
- 2003-10-13 CN CNA2003801013333A patent/CN1703423A/zh active Pending
- 2003-10-13 BR BR0315327-4A patent/BR0315327A/pt not_active IP Right Cessation
- 2003-10-13 EP EP03750224A patent/EP1554307A2/de not_active Withdrawn
- 2003-10-13 PL PL03376509A patent/PL376509A1/xx not_active Application Discontinuation
- 2003-10-13 WO PCT/CH2003/000666 patent/WO2004035622A2/de active Application Filing
- 2003-10-13 MX MXPA05003887A patent/MXPA05003887A/es unknown
- 2003-10-13 US US10/530,987 patent/US20060236411A1/en not_active Abandoned
- 2003-10-13 AU AU2003269659A patent/AU2003269659A1/en not_active Abandoned
- 2003-10-13 CA CA002502316A patent/CA2502316A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041232A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
Non-Patent Citations (4)
Title |
---|
PETTIT DEAN K ET AL: "Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling" JOURNAL OF BIOLOGICAL CHEMISTRY, Bd. 272, Nr. 4, 1997, Seiten 2312-2318, XP002042891 ISSN: 0021-9258 * |
RUECKERT R ET AL: "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, Bd. 28, Nr. 10, Oktober 1998 (1998-10), Seiten 3312-3320, XP002230807 ISSN: 0014-2980 * |
See also references of EP1554307A2 * |
ZHENG X X ET AL: "IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, Bd. 163, Nr. 7, 1. Oktober 1999 (1999-10-01), Seiten 4041-4048, XP002230805 ISSN: 0022-1767 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
CN100334112C (zh) * | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
CN101360827B (zh) * | 2005-10-20 | 2013-03-20 | 国立医学与健康研究所 | IL-15Rα sushi结构域作为通过IL-15Rβ/γ的IL-15作用的选择性和有效的增强剂以及超激动剂(IL15Rα sushi-IL15)融合蛋白 |
US10358477B2 (en) | 2005-10-20 | 2019-07-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain—IL-15 fusion proteins |
WO2013004587A1 (en) | 2011-07-01 | 2013-01-10 | F. Hoffmann-La Roche Ag | Method for separation of monomeric polypeptides from aggregated polypeptides |
US11401312B2 (en) | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
WO2014207173A1 (en) * | 2013-06-27 | 2014-12-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases |
US10202433B2 (en) | 2013-06-27 | 2019-02-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids |
KR20170094341A (ko) * | 2014-12-19 | 2017-08-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 인터류킨 15 단백질 복합체 및 그의 용도 |
KR102609197B1 (ko) | 2014-12-19 | 2023-12-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 인터류킨 15 단백질 복합체 및 그의 용도 |
US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
WO2004035622A3 (de) | 2004-07-08 |
JP2006518583A (ja) | 2006-08-17 |
KR20050049545A (ko) | 2005-05-25 |
AU2003269659A1 (en) | 2004-05-04 |
CN1703423A (zh) | 2005-11-30 |
RU2005114526A (ru) | 2005-10-10 |
PL376509A1 (en) | 2005-12-27 |
MXPA05003887A (es) | 2005-10-18 |
EP1554307A2 (de) | 2005-07-20 |
BR0315327A (pt) | 2005-08-16 |
US20060236411A1 (en) | 2006-10-19 |
CA2502316A1 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1554307A2 (de) | Il-15 antagonisten | |
DE69633617T2 (de) | Il-17 receptor | |
DE69836088T2 (de) | Als lerk6 bezeichnetes cytokin | |
DE60034579T2 (de) | Baff rezeptor (bcma), ein immunoregulatorisches mittel | |
DE69837606T2 (de) | Cystein-reiche rezeptoren-train | |
DE69534593T2 (de) | Onkostatin- m rezeptor | |
DE69434168T2 (de) | Liganden für die FLT3 Rezeptoren | |
DE69929019T2 (de) | Mu-1, ein mitglied der zytokinrezeptor-familie | |
DE69733610T2 (de) | Interleukin-15 antagonisten | |
US6605279B2 (en) | Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands | |
DE69838061T2 (de) | Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine | |
DE69534235T2 (de) | Cytokin lerk-7 | |
DE60131456T2 (de) | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern | |
DE69933216T2 (de) | Erythropoietin-analog-menschliches serum-albumin fusionsprotein | |
DE60004635T2 (de) | Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort | |
DE69535719T2 (de) | Fas-antigenbindender ligand | |
US6130316A (en) | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore | |
EP1017723A2 (de) | Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung | |
DE19821060A1 (de) | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung | |
JPH08511251A (ja) | f1t3受容体に対するリガンド | |
DE69535063T2 (de) | Denaturierter low-density lipoprotein (ldl) rezeptor | |
EP1586585A1 (de) | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung | |
DE69535316T2 (de) | Als lerk6 bezeichnetes cytokin | |
US6824779B1 (en) | Methods for inhibiting the interaction of B7-2 with its natural ligand | |
DE60119517T2 (de) | Cd154 varianten und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/003887 Country of ref document: MX Ref document number: 2003269659 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2502316 Country of ref document: CA Ref document number: 1020057006381 Country of ref document: KR Ref document number: 20038A13333 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 376509 Country of ref document: PL Ref document number: 2004543889 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003750224 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005114526 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006381 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003750224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006236411 Country of ref document: US Ref document number: 10530987 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10530987 Country of ref document: US |